Gerrish Amy, Stone Edward, Clokie Samuel, Ainsworth John R, Jenkinson Helen, McCalla Maureen, Hitchcott Carol, Colmenero Isabel, Allen Stephanie, Parulekar Manoj, Cole Trevor
West Midlands Regional Genetics Service, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
West Midlands Regional Genetics Service, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Br J Ophthalmol. 2019 Feb 11;103(5):721-4. doi: 10.1136/bjophthalmol-2018-313005.
Retinoblastoma is the most common eye malignancy in childhood caused by mutations in the gene. Both alleles of the gene must be mutated for tumour development. The initial mutation may be constitutional germline or somatic (originating in one retinal cell only). Distinguishing between these alternative mechanisms is crucial, with wider implications for management of the patient and family members. Bilateral retinoblastoma is nearly always due to a constitutional mutation; however, approximately 15% of unilateral cases also carry a germline mutation, and identifying these cases is important. This can be achieved by identifying both mutation types in tumour tissue and excluding their presence in blood. Modern eye-saving chemotherapy treatment (systemic, intra-arterial and intravitreal) has resulted in fewer enucleations. As a result, tumour tissue required to identify sporadic mutation(s) is not always available. Modern intravitreal chemotherapeutic techniques for retinoblastoma involve aspiration of aqueous humour (AH), providing a novel sample source for analysis. By analysing cell-free DNA present in the AH fluid of eyes affected with retinoblastoma, we have developed a screening test capable of detecting somatic mutations that is comparable to current tests on enucleated tumour tissue. The results obtained with fluid from enucleated eyes were concordant with tumour tissue in all 10 cases analysed. In addition, AH analysis from two patients undergoing intravitreal chemotherapy successfully identified somatic variants in both cases. Our findings suggest that AH fluid is a promising source of tumour-derived DNA in retinoblastoma for analysis.
视网膜母细胞瘤是儿童期最常见的眼部恶性肿瘤,由该基因的突变引起。该基因的两个等位基因都必须发生突变才能导致肿瘤发展。最初的突变可能是遗传性种系突变或体细胞突变(仅起源于一个视网膜细胞)。区分这些不同的机制至关重要,这对患者及其家庭成员的管理具有更广泛的意义。双侧视网膜母细胞瘤几乎总是由遗传性突变引起;然而,约15%的单侧病例也携带种系突变,识别这些病例很重要。这可以通过在肿瘤组织中识别两种突变类型并排除其在血液中的存在来实现。现代的挽救视力的化疗治疗(全身、动脉内和玻璃体内)减少了眼球摘除术的实施。因此,识别散发性突变所需的肿瘤组织并不总是可得的。视网膜母细胞瘤的现代玻璃体内化疗技术涉及抽取房水(AH),这为分析提供了一种新的样本来源。通过分析视网膜母细胞瘤患者眼内房水液中存在的游离DNA,我们开发了一种筛查试验,能够检测体细胞突变,其与目前对摘除的肿瘤组织进行的检测相当。在分析的所有10例病例中,从摘除眼球获得的液体检测结果与肿瘤组织检测结果一致。此外,对两名接受玻璃体内化疗的患者进行的房水分析在两例中均成功识别出体细胞变异。我们的研究结果表明,房水液是视网膜母细胞瘤中用于分析的有前景的肿瘤衍生DNA来源。